ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1959

Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database

Pierre-Antoine Juge1, Lidwine Wemeau2, Sebastien Ottaviani3, guillaume desjeux4, Joe Zhuo5, Virginie Vannier-Moreau6, René-Marc Flipo7, Bruno Crestani8 and Philippe Dieude9, 1Rheumatology department, Bichat Hospital, Paris, France, 2Pulmonology department, Lille University hospital, Lille, France, 3Hopital Bichat-Claude Bernard, Paris, France, 4e-Health Services Sanoia, Gemenos, France, 5BMS, Lawrenceville, NJ, 6BMS, Rueil-Malmaison, 7Hôpital Roger Salengro, Lille, France, 8Hopital Bichat, Paris University, Paris, France, 9Université Paris Cité, Paris, France

Meeting: ACR Convergence 2022

Keywords: Epidemiology, interstitial lung disease, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster IV

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Interstitial lung disease (ILD) is a common extra-articular manifestation of RA. Studies have shown variability in the prevalence and mortality rate of patients with RA-associated ILD (RA-ILD). Further efforts are needed to better characterize the burden of ILD in patients with RA. Our objective was to compare the mortality rate in RA with and without ILD and to identify factors affecting mortality in patients with RA-ILD.

Methods: Data were analyzed from SNDS, the French national claims database, from between January 1, 2013, and December 31, 2018. Adults with an RA diagnosis (International Classification of Diseases, Tenth Revision [ICD-10] codes M05, M06.0, M06.8, and M06.9) and ≥ 2 distinct dates of DMARD delivery were included. ILD diagnosis was defined as having ICD-10 code J84 and ≥ 1 CT scan within 1 year of the first date of ILD occurrence. The mortality rates were compared between patients with RA-ILD and patients with RA without ILD (RA-noILD) and were matched 1:1 for age, sex, age at RA-ILD onset, and duration of RA using Cox proportional hazards regression.

Results: Among the 173,132 patients with RA, ILD was identified in 4330 (2.5%). In patients with RA-ILD, mean age at RA onset was 63.3 ± 13.7 years and 39.8% were male. ILD onset occurred after RA onset in 71.6% of patients, concomitant with RA onset (± 1 year of RA onset) in 25.8%, and before RA onset in 2.5%. After matching, RA-ILD was associated with an increased mortality rate (hazard ratio [HR], 3.4; 95% confidence interval [CI], 3.1–3.9; Figure 1). Sensitivity analyses according to cardiovascular comorbidities and risk factors showed similar findings. The increased mortality rate was higher in patients aged < 75 years (HR, 4.8; 95% CI, 3.9–5.9) compared with patients aged > 75 years (HR, 3.0; 95% CI, 2.6–3.5); patients with ILD onset occurring before RA onset (HR, 8.4; 95% CI, 5.5–13.0) compared with patients with concomitant onset (HR, 5.3; 95% CI, 4.6–6.2) and with patients with ILD onset after RA onset (HR, 2.9; 95% CI, 2.6–3.3); and male patients (HR, 5.2; 95% CI, 4.4–6.2) compared with female patients (HR, 3.6; 95% CI, 3.0–4.2). The number of patients with ≥ 1 hospitalization was 1.45 times greater for patients with RA-ILD compared with RA-noILD.

Conclusion: In this nationwide cohort study, RA-ILD was associated with a strong increase in mortality rate in patients with RA, notably in younger patients, males, and patients whose ILD occurred before RA onset.

Supporting image 1


Disclosures: P. Juge, Bristol-Myers Squibb(BMS), Novartis, AstraZeneca, Boehringer-Ingelheim; L. Wemeau, Boehringer-Ingelheim, Bristol-Myers Squibb(BMS), Roche, Sanofi, Pfizer; S. Ottaviani, None; g. desjeux, None; J. Zhuo, Bristol-Myers Squibb(BMS); V. Vannier-Moreau, Bristol-Myers Squibb(BMS); R. Flipo, AbbVie/Abbott, Biogen, Bristol-Myers Squibb(BMS), Eli Lilly, Janssen, MSD, Mylan, Nordic Pharma France, Novartis, Pfizer, Roche-Chugaï, Sandoz, Sanofi, UCB; B. Crestani, Roche, Boehringer-Ingelheim; P. Dieude, None.

To cite this abstract in AMA style:

Juge P, Wemeau L, Ottaviani S, desjeux g, Zhuo J, Vannier-Moreau V, Flipo R, Crestani B, Dieude P. Increased Mortality in Patients with RA-Associated Interstitial Lung Disease: Data from a French Administrative Healthcare Database [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/increased-mortality-in-patients-with-ra-associated-interstitial-lung-disease-data-from-a-french-administrative-healthcare-database/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-mortality-in-patients-with-ra-associated-interstitial-lung-disease-data-from-a-french-administrative-healthcare-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology